Case Report: Definitive radiotherapy for intrathyroidal thymic carcinoma with neuroendocrine differentiation
- 1The First Clinical Medicine College, Gansu University of Chinese Medicine , ,
- 2Department of Radiotherapy, Gansu Provincial Hospital , ,
Abstract
Intrathyroidal thymic carcinoma (ITTC) with neuroendocrine differentiation is rare, and evidence for definitive radiotherapy in nonsurgical patients remains limited. A 70-year-old woman with a 1-year history of a neck mass and hoarseness was diagnosed with ITTC with neuroendocrine differentiation based on histopathological, immunohistochemical, and imaging findings. After declining surgery and systemic chemotherapy, she received definitive radiotherapy: 60 Gy in 30 fractions to the planning target volume, followed by a sequential boost of 6 Gy in 3 fractions to the gross primary tumor and involved lymph nodes, for a cumulative dose of 66 Gy in 33 fractions. No grade ≥3 acute treatment-related toxicities occurred. At approximately 2 months after radiotherapy, the sum of target-lesion diameters decreased from 54 mm to 42 mm, a 22.2% reduction. With no new lesions or unequivocal progression of non-target disease, the overall response was classified as stable disease according to RECIST 1.1. This case documents early radiographic tumor reduction following definitive radiotherapy for ITTC, although longer follow-up is required to assess the durability of disease control and late toxicity.
Related
- Integration of Immune checkpoint inhibitors within the definitive radiotherapy-based treatment continuum for locally advanced mucosal head and neck squamous cell carcinoma: a scoping review protocol
- Definitive radiotherapy versus surgery after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma: a propensity score-matched study of efficacy and safety
- Overtreatment risk of postoperative radiotherapy in FIGO I–III cervical small cell neuroendocrine carcinoma: a population-based study
- Prognostic Significance of the ESTRO/EORTC Classification of Oligometastatic Disease for Colorectal Cancer Patients With Uncommon Metastases Treated With Definitive Radiotherapy
- Definitive Hypofractionated Radiotherapy in Elderly Patients With Non-melanoma Skin Cancer: Predicting Complete Response Using a Machine Learning-based Approach
BibTeX
@article{du2026case,
title = {{Case Report: Definitive radiotherapy for intrathyroidal thymic carcinoma with neuroendocrine differentiation}},
author = {Jia Du and Jiankai Wang and Jianbing Song and Yunzhi Xu and Xiaoyu Duan and Hongyi Cai},
journal = {Frontiers in oncology},
year = {2026},
month = sep,
doi = {10.3389/fonc.2026.1944330},
url = {https://europepmc.org/article/PMC/PMC13661400},
note = {CC BY},
}
RIS
TY - JOUR
TI - Case Report: Definitive radiotherapy for intrathyroidal thymic carcinoma with neuroendocrine differentiation
AU - Jia Du
AU - Jiankai Wang
AU - Jianbing Song
AU - Yunzhi Xu
AU - Xiaoyu Duan
AU - Hongyi Cai
PY - 2026
DA - 2026/09/30
JO - Frontiers in oncology
DO - 10.3389/fonc.2026.1944330
UR - https://europepmc.org/article/PMC/PMC13661400
AB - Intrathyroidal thymic carcinoma (ITTC) with neuroendocrine differentiation is rare, and evidence for definitive radiotherapy in nonsurgical patients remains limited. A 70-year-old woman with a 1-year history of a neck mass and hoarseness was diagnosed with ITTC with neuroendocrine differentiation based on histopathological, immunohistochemical, and imaging findings. After declining surgery and systemic chemotherapy, she received definitive radiotherapy: 60 Gy in 30 fractions to the planning target volume, followed by a sequential boost of 6 Gy in 3 fractions to the gross primary tumor and involved lymph nodes, for a cumulative dose of 66 Gy in 33 fractions. No grade ≥3 acute treatment-related toxicities occurred. At approximately 2 months after radiotherapy, the sum of target-lesion diameters decreased from 54 mm to 42 mm, a 22.2% reduction. With no new lesions or unequivocal progression of non-target disease, the overall response was classified as stable disease according to RECIST 1.1. This case documents early radiographic tumor reduction following definitive radiotherapy for ITTC, although longer follow-up is required to assess the durability of disease control and late toxicity.
SN - 2234-943X
ER -